Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceralasertib - AstraZeneca/University of Pennsylvania

Drug Profile

Ceralasertib - AstraZeneca/University of Pennsylvania

Alternative Names: AZD 6738

Latest Information Update: 17 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca; University of Pennsylvania
  • Developer Acerta Pharma; AstraZeneca; Dana-Farber Cancer Institute; Gustave Roussy; National Cancer Institute (France); Samsung Medical Center; University of California at San Francisco; University of Pennsylvania
  • Class Antineoplastics; Cyclopropanes; Imines; Ketones; Morpholines; Organic sulfur compounds; Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Cholangiocarcinoma; Gastric cancer; Gynaecological cancer; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
  • Phase I/II Chronic lymphocytic leukaemia
  • Preclinical Diffuse large B cell lymphoma; Type 1 diabetes mellitus
  • No development reported B-cell lymphoma; Chronic myelomonocytic leukaemia; Head and neck cancer; Lymphoid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Discontinued Haematological malignancies

Most Recent Events

  • 08 Jan 2024 NHS Greater Glasgow, Clyde Health Board and AstraZeneca terminates a Phase-II clinical trials in Pancreatic cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, In adolescents, In adults, In the elderly) in United Kingdom (PO)due to lack of staff/facilities/resources as of January 2024 (EudraCT2018-003971-37) (ISRCTN16004234)
  • 25 Oct 2023 Samsung Medical Center in collaboration with AstraZeneca completes a phase II SUKSES-N4 trial for Small cell lung cancer (Combination therapy, Second line therapy or greater) in South Korea (IV) (NCT04361825)
  • 20 Oct 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in South Korea, USA (PO) (NCT02264678)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top